Cantor Fitzgerald Initiates Coverage On Generate Biomedicines with Overweight Rating

Benzinga Newsdesk www.benzinga.com Neutral 70.3%

Neg 0% Neu 70.3% Pos 0%

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating.